Last reviewed · How we verify
Butenafine HCl 1% (BAY1896425)
Butenafine HCl 1% (BAY1896425) is a Allylamine antifungal Small molecule drug developed by Bayer. It is currently in Phase 3 development for Fungal skin infections (dermatophytosis, tinea pedis, tinea corporis, tinea cruris). Also known as: Antifungal Cream V61-044 containing Trolamine.
Butenafine HCl is an allylamine antifungal that disrupts fungal cell membrane integrity by inhibiting squalene epoxidase, leading to ergosterol depletion.
Butenafine HCl is an allylamine antifungal that disrupts fungal cell membrane integrity by inhibiting squalene epoxidase, leading to ergosterol depletion. Used for Fungal skin infections (dermatophytosis, tinea pedis, tinea corporis, tinea cruris).
At a glance
| Generic name | Butenafine HCl 1% (BAY1896425) |
|---|---|
| Also known as | Antifungal Cream V61-044 containing Trolamine |
| Sponsor | Bayer |
| Drug class | Allylamine antifungal |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Butenafine inhibits the fungal enzyme squalene epoxidase, which is critical for ergosterol synthesis in the fungal cell membrane. This causes accumulation of squalene and depletion of ergosterol, destabilizing the fungal cell membrane and resulting in fungal cell death. It is effective against dermatophytes, yeasts, and other fungi causing topical infections.
Approved indications
- Fungal skin infections (dermatophytosis, tinea pedis, tinea corporis, tinea cruris)
Common side effects
- Contact dermatitis
- Local irritation
- Erythema
- Pruritus
Key clinical trials
- Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test) (PHASE3)
- Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants (PHASE3)
- Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects (PHASE3)
- Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butenafine HCl 1% (BAY1896425) CI brief — competitive landscape report
- Butenafine HCl 1% (BAY1896425) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Butenafine HCl 1% (BAY1896425)
What is Butenafine HCl 1% (BAY1896425)?
How does Butenafine HCl 1% (BAY1896425) work?
What is Butenafine HCl 1% (BAY1896425) used for?
Who makes Butenafine HCl 1% (BAY1896425)?
Is Butenafine HCl 1% (BAY1896425) also known as anything else?
What drug class is Butenafine HCl 1% (BAY1896425) in?
What development phase is Butenafine HCl 1% (BAY1896425) in?
What are the side effects of Butenafine HCl 1% (BAY1896425)?
What does Butenafine HCl 1% (BAY1896425) target?
Related
- Drug class: All Allylamine antifungal drugs
- Target: All drugs targeting Squalene epoxidase
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Dermatology / Infectious Disease
- Indication: Drugs for Fungal skin infections (dermatophytosis, tinea pedis, tinea corporis, tinea cruris)
- Also known as: Antifungal Cream V61-044 containing Trolamine
- Compare: Butenafine HCl 1% (BAY1896425) vs similar drugs
- Pricing: Butenafine HCl 1% (BAY1896425) cost, discount & access